Prostate cancer, a leading cause of cancer among men in Kenya and worldwide, has long resisted effective treatment through immunotherapy. However, a recent study published in Nature Biomedical Engineering reveals a novel RNA-based approach that could change this.

Typically, prostate tumors are "immune cold," meaning they attract few T cells—the immune system's key cancer-fighting cells—making immunotherapy less effective. Researchers discovered that in prostate cancer cells, certain RNA molecules become abnormally shortened, prompting the production of a protein called SPSB1. This protein removes the MHC-1 complex, a vital marker that signals T cells to attack the cancer cells. Without this marker, cancer cells evade immune detection.

The team engineered a CRISPR-derived tool that targets RNA instead of DNA, restoring the RNA to its normal length. This correction reduces SPSB1 levels, allowing the MHC-1 markers to reappear on cancer cells, thereby enhancing immune recognition.

When combined with immunotherapy in laboratory mice, this RNA treatment led to increased infiltration of immune cells into tumors and improved cancer cell destruction compared to immunotherapy alone. Importantly, no significant side effects were observed in these preclinical tests.

Implications and Future Steps

  • Prostate cancer accounts for approximately 3,601 new cases annually in Kenya, representing 10% of all cancer cases.
  • Immunotherapy has revolutionized treatment for several cancers but struggles against prostate and other "immune cold" tumors.
  • This RNA therapy could potentially extend to other difficult-to-treat cancers like pancreatic cancer.
  • Further laboratory research and human clinical trials are necessary to establish safety and efficacy.

Experts highlight that RNA-based therapies offer a promising avenue by temporarily modifying genetic messages without altering DNA, potentially reducing long-term risks. While the technology remains in early stages and is not yet available for patients, it represents a significant step toward overcoming a major hurdle in cancer treatment: enabling the immune system to identify and attack previously hidden tumors.

This breakthrough provides renewed hope for improved outcomes in prostate cancer treatment, a disease that affects millions globally.